• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

How eClinicalWorks Agentic AI Is Helping Revenue Cycle Leaders Improve Financial Performance
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Mindstrong Health, Takeda Partner to Develop Digital Biomarkers for Mental Health Conditions

by Fred Pennic 02/28/2018 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Mindstrong Health, Takeda Partner to Develop Digital Biomarkers for Mental Health Conditions

Mindstrong Health, a digital health startup transforming the diagnosis and treatment of neuropsychiatric disorders, has entered into a partnership with Takeda Pharmaceutical Company Limited to explore the development of digital biomarkers for selected mental health conditions, in particular schizophrenia and treatment-resistant depression.

In this decade, neuropsychiatric disorders represent the largest source of medical disability for people under age 50. The costs are among the highest of all medical disorders, in part because mental disorders begin early and can result in many years lost to disability.

For people in the second half of life, neurodegenerative disorders are becoming increasingly prevalent, with dementia affecting one in three over age 80. Our best hope for improving outcomes for people with neurodevelopmental and neurodegenerative disorders is early prediction and preemptive interventions.

Mindstrong Health has developed digital biomarkers that continuously measure brain function from passively collected smartphone data. Takeda’s technology, combined with the powerful Mindstrong Health platform will potentially enable the application of digital biomarkers to stratify mental health conditions and predict remission with novel therapeutic interventions.

Digital phenotyping is the core of Mindstrong Health’s measurement approach. Digital phenotyping is simply assessment based on smartphone use.  As smartphones have become ubiquitous, their increasing use provides an unprecedented opportunity to measure mood, cognition, and behavior – passively, objectively, and continuously.

“Takeda shares our goal of using innovative technology to gain insights that will improve outcomes for people living with mental health conditions,” said Dr. Paul Dagum, Founder and CEO of Mindstrong Health in a statement. “We are pleased to partner with them to implement digital technology in the clinical development of novel assets and, hopefully, allow for faster delivery of meaningful therapies to patients.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Digital Biomarkers, Digital phenotyping, Mindstrong Health, neuropsychiatric disorders, Takeda Pharmaceutical

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

How eClinicalWorks Agentic AI Is Helping Revenue Cycle Leaders Improve Financial Performance

Most-Read

Innovaccer-CHIME 2030 Survey Reveals AI Will Automate Nearly Two-Thirds of Administrative Work and Do 3x the Work With the Same Staff

Innovaccer-CHIME 2030 Survey Reveals AI Will Automate Nearly Two-Thirds of Administrative Work and Do 3x the Work With the Same Staff

CB Insights’ 2026 Digital Health 50 Reveals How Agentic AI Is Becoming the Clinical Provider and Medication Access Engine

Oura Acquires Counsel Health for $625M: Scaling Continuous Biometrics into On-Demand Medical Care

M&A: Oura Acquires Counsel Health for $625M: Scaling Continuous Biometrics into On-Demand Medical Care

WittKieffer 2026 Healthcare CIO Survey: 82% Sit on Executive Teams, Yet Only 36% Have Formal Succession Plans

WittKieffer 2026 Healthcare CIO Survey: 82% Sit on Executive Teams, Yet Only 36% Have Formal Succession Plans

CVS Rebrands Health Services Segment, Launches Model for Retail Pharmacy Reimbursement

CVS Health Formalizes Tax-Free Split-Off to Carve Out CVS Pharmacy by 2028

SAMHSA and ONC Invest $20M in Behavioral Health IT Initiative

ONC Finalizes HTI-5 Deregulatory Rule to Cut $1.55B in Health IT Compliance and Accelerate FHIR APIs

Redesign Health Merges with Sheba Medical Center’s ARC Global and Agrees to Acquire AVIA

Redesign Health Merges with Sheba Medical Center’s ARC Global and Agrees to Acquire AVIA

Sword Acquires Headspace in All-Cash Deal Worth Up to $300M to Unify Physical and Mental AI Care

M&A: Sword Acquires Headspace in All-Cash Deal Worth Up to $300M to Unify Physical and Mental AI Care

M&A: Francisco Partners to Acquire Weave in $650M Take-Private Deal

M&A: Francisco Partners to Acquire Weave in $650M Take-Private Deal

Epic Launches One-Click Care Everywhere Diagnostic Image Exchange

Epic Launches One-Click Care Everywhere Diagnostic Image Exchange

Secondary Sidebar

Footer

Company

  • About Us
  • 2026 Editorial Calendar
  • Advertise with Us
  • Reprints and Permissions
  • Op-Ed Submission Guidelines
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2026. HIT Consultant Media. All Rights Reserved. Privacy Policy |